They concluded that EVs derived from hypoxia-treated BMSCs facilitate lung cancer progression by delivering miR-328-3p, which targets and inhibits the NF2 gene, thereby inhibiting the Hippo signaling pathway. The gene discussed is NF2; the disease is lung cancer.